Company intelligence

HUMA

Humacyte, Inc. · NASDAQ · Healthcare

Price$0.69+1.28% · +$0.01

Market cap115.97MEquity value

P / E-1.1Trailing ratio

Volume2.63MLatest session

Market data

HUMA price chart

TradingView

Related signals

1 min delayed

Browse public HUMA signals with their source context and measured market impact. Open any signal for its permanent analysis page.

HUMADec 20, 2024+34.10% since signal

Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday?

FDA approved Humacyte’s Symvess for use in urgent vascular cases. Symvess offers quick, off-the-shelf implantation without further patient injury. Real-world data from wartime interventions supports Symvess's effectiveness. Humacyte's stock surged 58.1% to $5.47 after the FDA approval.

View signal analysis

Research